PDCD1 and renal cell carcinoma: INCAGN02385 (monoclonal antibody anti-LAG3) and XmAb®22841 (bispecific antibody anti-LAG3 and anti-CTLA-4) are also drugs being tested as monotherapy or in combination with anti-PD-1 drugs in a variety of solid tumors including RCC [55,56].